Esophageal Cancer Molecular Diagnostics Market - Top Companies and Manufacturers

Top Featured Companies Dominating the Esophageal Cancer Molecular Diagnostics Landscape

The global burden of oesophageal cancer can be minimized by the collaborative efforts of the various diagnostic companies, alongside the latest medical advancements to tackle the disease. By the day, the technological innovations in the Esophageal Cancer Molecular Diagnostics industry are expected to tackle the malignancy in the earlier stages and push up the survival rate.

Roche Diagnostics
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Siemens Healthineers
Thermo Fisher Scientific
Illumina Inc.
GE Healthcare
Becton, Dickinson and Company
Abbott Laboratories Inc.
bioMérieux
Agilent Technologies, Inc.
Hologic, Inc.
Otsuka Pharmaceutical Co., Ltd
Chordia Therapeutics
AI Medical Service

Browse Key Market Insights with Data Illustration:

Esophageal Cancer Molecular Diagnostics Market Size Forecasts 2036

In the News

• Roche Diagnostics- Roche Diagnostics has welcomed the latest novelty in breast cancer to enable targeted therapy for metastatic cancer via the HER 2-low status. Roche acquired parts of Point-of-Care technology from LumiraDx to facilitate user-friendly and accessible testing to patients globally. The goal is to transform Point-of-Care testing across its various centers, not limiting itself to certain diseases.

•Siemens Healthineers- Siemens Healthineers is harnessing the potential of the cloud by partnering with SAP by migrating to its solutions. Post the successful pilot run with RISE, Siemens is set to pave the path toward transforming digitally.

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of esophageal cancer molecular diagnostics was over USD 4 billion.

The market size for esophageal cancer diagnostics is forecasted to cross USD 11.54 billion by the end of 2036 expanding at a CAGR of 7.65% in the predicted timeline mentioned i.e., between 2024-2036.

The major players in the market are Roche Diagnostics, Chordia Therapeutics, Otsuka Pharmaceutical Co., Ltd, Agilent Technologies, Inc., Thermo Fisher Scientific, Illumina Inc., and others.

The genetic tests segment is anticipated to achieve a share/size of 55% during 2024-2036.

The Asia Pacific esophageal cancer molecular diagnostics sector is poised to hold a 60% share by the end of 2036.

Esophageal Cancer Molecular Diagnostics Market - Top Companies and Manufacturers

Top Featured Companies Dominating the Esophageal Cancer Molecular Diagnostics Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the esophageal cancer molecular diagnostics industry?

What is the outlook for the esophageal cancer molecular diagnostics market?

Who are the major players dominating the esophageal cancer molecular diagnostics landscape?

Which segment will capture the significant market share for esophageal cancer molecular diagnostics by 2036?

Which region will provide more opportunities for esophageal cancer molecular diagnostics in the near future?